Use of intravenous humana immunoglobulin in rheumatic diseases

Introduction: Preparations of intravenous immunoglobulin (IVIG) are used as treatment in different diseases such primary and secondary immunodeficiencies, autoimmune diseases, systemic inflammatory diseases, infectious diseases and allergic diseases among others.Objective: to present 13 of our cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Mussano, Eduardo D., Onetti, Laura B., Cadile, Isaac I., Onetti, Carlos M.
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2018
Materias:
inmunoglobulina endovenosa
enfermedades reumáticas
eficacia terapéutica
intravenous immunoglobulin
rheumatic diseases
therapeutic efficacy
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/21339
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-21339
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
language Español
format Artículo revista
topic inmunoglobulina endovenosa
enfermedades reumáticas
eficacia terapéutica
intravenous immunoglobulin
rheumatic diseases
therapeutic efficacy
spellingShingle inmunoglobulina endovenosa
enfermedades reumáticas
eficacia terapéutica
intravenous immunoglobulin
rheumatic diseases
therapeutic efficacy
Mussano, Eduardo D.
Onetti, Laura B.
Cadile, Isaac I.
Onetti, Carlos M.
Use of intravenous humana immunoglobulin in rheumatic diseases
topic_facet inmunoglobulina endovenosa
enfermedades reumáticas
eficacia terapéutica
intravenous immunoglobulin
rheumatic diseases
therapeutic efficacy
author Mussano, Eduardo D.
Onetti, Laura B.
Cadile, Isaac I.
Onetti, Carlos M.
author_facet Mussano, Eduardo D.
Onetti, Laura B.
Cadile, Isaac I.
Onetti, Carlos M.
author_sort Mussano, Eduardo D.
title Use of intravenous humana immunoglobulin in rheumatic diseases
title_short Use of intravenous humana immunoglobulin in rheumatic diseases
title_full Use of intravenous humana immunoglobulin in rheumatic diseases
title_fullStr Use of intravenous humana immunoglobulin in rheumatic diseases
title_full_unstemmed Use of intravenous humana immunoglobulin in rheumatic diseases
title_sort use of intravenous humana immunoglobulin in rheumatic diseases
description Introduction: Preparations of intravenous immunoglobulin (IVIG) are used as treatment in different diseases such primary and secondary immunodeficiencies, autoimmune diseases, systemic inflammatory diseases, infectious diseases and allergic diseases among others.Objective: to present 13 of our cases with the use of IVIG in different rheumatic diseases.Patients and methods: we retrospectively studied 13 patients (10 women and 3 men), mean age 29 years with different rheumatic diseases, that underwent conventional treatments without positive response. They received IVIG pulses, trying to improve or induce remission of their previous clinical situation. 6/13 patients met criteria for systemic lupus erythematosus (SLE), 2/13 had primary antiphospholipid syndrome (APL)one had polydermatomyositis (PDM), 1 juvenile arthritis, 1 panarteritis nodosa (cutaneous PAN), one Evans syndrome, and one with autoimmune uveitis.Results: 7 of them had a positive response to therapy with IGEV evaluated by clinical and biochemical parameters. They remained with conventional treatments. One patient received a new IG EV pulse after 24 months, because of panniculitis reactivation. Clinical and biochemical response was poor in 4 of them, and 2 patients died.Conclusion: IVIg may be usefull in autoimmune rheumatic diseases when conventional therapies have failed. The therapeutic success is also limited. Only the 55 percent of our patients had a positive clinical response.
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2018
url https://revistas.unc.edu.ar/index.php/med/article/view/21339
work_keys_str_mv AT mussanoeduardod useofintravenoushumanaimmunoglobulininrheumaticdiseases
AT onettilaurab useofintravenoushumanaimmunoglobulininrheumaticdiseases
AT cadileisaaci useofintravenoushumanaimmunoglobulininrheumaticdiseases
AT onetticarlosm useofintravenoushumanaimmunoglobulininrheumaticdiseases
AT mussanoeduardod usodeinmunoglobulinaghumanaendovenosaigevenenfermedadesreumaticas
AT onettilaurab usodeinmunoglobulinaghumanaendovenosaigevenenfermedadesreumaticas
AT cadileisaaci usodeinmunoglobulinaghumanaendovenosaigevenenfermedadesreumaticas
AT onetticarlosm usodeinmunoglobulinaghumanaendovenosaigevenenfermedadesreumaticas
first_indexed 2024-09-03T20:59:51Z
last_indexed 2024-09-03T20:59:51Z
_version_ 1809210085802508288
spelling I10-R327-article-213392024-08-27T18:23:01Z Use of intravenous humana immunoglobulin in rheumatic diseases Uso de inmunoglobulina G humana endovenosa (IGEV) en enfermedades reumáticas Mussano, Eduardo D. Onetti, Laura B. Cadile, Isaac I. Onetti, Carlos M. inmunoglobulina endovenosa enfermedades reumáticas eficacia terapéutica intravenous immunoglobulin rheumatic diseases therapeutic efficacy Introduction: Preparations of intravenous immunoglobulin (IVIG) are used as treatment in different diseases such primary and secondary immunodeficiencies, autoimmune diseases, systemic inflammatory diseases, infectious diseases and allergic diseases among others.Objective: to present 13 of our cases with the use of IVIG in different rheumatic diseases.Patients and methods: we retrospectively studied 13 patients (10 women and 3 men), mean age 29 years with different rheumatic diseases, that underwent conventional treatments without positive response. They received IVIG pulses, trying to improve or induce remission of their previous clinical situation. 6/13 patients met criteria for systemic lupus erythematosus (SLE), 2/13 had primary antiphospholipid syndrome (APL)one had polydermatomyositis (PDM), 1 juvenile arthritis, 1 panarteritis nodosa (cutaneous PAN), one Evans syndrome, and one with autoimmune uveitis.Results: 7 of them had a positive response to therapy with IGEV evaluated by clinical and biochemical parameters. They remained with conventional treatments. One patient received a new IG EV pulse after 24 months, because of panniculitis reactivation. Clinical and biochemical response was poor in 4 of them, and 2 patients died.Conclusion: IVIg may be usefull in autoimmune rheumatic diseases when conventional therapies have failed. The therapeutic success is also limited. Only the 55 percent of our patients had a positive clinical response. Introducción: Las preparaciones de inmunoglobulina endovenosa (IGEV) son utilizadas como terapia en diversas enfermedades como: inmunodeficiencias primarias (IDP) y secundarias (IDS), enfermedades autoinmunes (EAI) e inflamatorias sistémicas (ENFSIS), enfermedades infecciosas y enfermedades alérgicas entre otras.Objetivo: presentar una casuística en el uso de IGEV en distintas enfermedades reumáticas.Pacientes y métodos: se estudiaron en forma retrospectiva 10 mujeres y 3 hombres, edad media de 29 años a quienes, por refractariedad a tratamientos convencionales, se realizaron pulsos de IGEV para tratar de lograr mejoría o remisión de su cuadro clínico previo. Del total de pacientes 6/13 tenían lupus eritematoso sistémico (LES), 2/13 síndrome antifosfolípido primario (SAF 1º) y 1 caso de polidermatomiositis (PDM), 1 artritis crónica juvenil (ACJ), 1 panarteritis nodosa cutánea (PAN cutánea), un paciente con síndrome de Evans (SE) y un paciente con uveítis autoinmune (UA).Resultados: de 13 pacientes, 7 tuvieron una respuesta positiva a la terapia con IGEV evaluada por parámetros clínicos, bioquímicos y de calidad de vida que se prolongaron en el tiempo de seguimiento, Ellos quedaron con tratamientos convencionales. Una paciente después de 24 meses recibió nuevo pulso de IG EV por reactivación de su paniculitis lúpica. En 6 pacientes hubo fracaso terapéutico con la IGEV, ya que la respuesta clínica y bioquímica fue pobre en 4 de ellos, y 2 pacientes, fallecieron dentro del mes del último pulso, 1 por hemorragia pulmonar masiva y otro por sepsis.Conclusión: la IGEV puede ser una opción útil ante el fracaso de terapias convencionales en las enfermedades reumáticas autoinmunes, aunque el margen de éxito terapéutico también es limitado. Sólo el 55 por ciento de nuestros pacientes tuvieron una respuesta clínica positiva. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2018-09-17 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html https://revistas.unc.edu.ar/index.php/med/article/view/21339 10.31053/1853.0605.v69.n2.21339 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 69 No. 2 (2012); 83-89 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 69 Núm. 2 (2012); 83-89 Revista da Faculdade de Ciências Médicas de Córdoba; v. 69 n. 2 (2012); 83-89 1853-0605 0014-6722 10.31053/1853.0605.v69.n2 spa https://revistas.unc.edu.ar/index.php/med/article/view/21339/20849 Derechos de autor 2018 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares